CMS issues final 2023 Medicare Advantage, Part D prescription drug rules: 10 things to know
(By Jakob Emerson for Becker’s Hospital Review) CMS issued its final 2023 Medicare Advantage and Part D rule that aims
Read More
CMS
Medicare Advantage Organization denials of prior authorization requests raise concerns
(By Andrew Cass for Becker’s Hospital Review) A report from the HHS Office of the Inspector General released April 27
Read MoreHHS Announces New Policy to Make Coverage More Accessible and Affordable for Millions of Americans in 2023
(Source – www.cms.gov) The Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS),
Read MoreImplementing Certain Provisions of the Consolidated Appropriations Act, 2021 and other Revisions to Medicare Enrollment and Eligibility Rules (CMS-4199-P)
(Source – cms.gov/newsroom) On April 22, 2022 the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule to
Read MoreCMS updates COVID-19 testing rules for long-term care facilities
(By Cailey Gleeson for Becker’s Hospital Review) Long-term care residents and staff with symptoms or signs of COVID-19 must be
Read MorePayer organizations respond to CMS’ Medicare Advantage, Part D proposed rule
(By Georgina Gonzalez for Becker’s Hospital Review) America’s Health Insurance Plans and the Alliance of Community Health Plans have commented
Read MorePatients Divided Over Alzheimer’s Drug: Is It a ‘Risk I’m Willing to Take’ or Just a ‘Magic Pill’?
(By Judith Graham for Kaiser Health News) If you listen to the nation’s largest Alzheimer’s disease advocacy organizations, you might
Read MoreHow CMS looks at ‘fully vaccinated’ under mandate
(By Kelly Gooch for Becker’s Hospital Review) As CMS’ COVID-19 vaccination mandate is in effect nationwide, the agency is allowing
Read MoreCMS to launch monthly special enrollment period beginning in late March
(By Nick Moran for Becker’s Hospital Review) CMS’ new monthly special enrollment period for ACA marketplaces is slated to kick
Read MoreInside the Tactical Tug of War Over the Controversial Alzheimer’s Drug
(By Arthur Allen for Kaiser Health News) The drug industry, patient advocates, and congressional Republicans have all attacked federal officials’
Read More